PFG Investments LLC Has $612,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

PFG Investments LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 39.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,539 shares of the medical instruments supplier’s stock after buying an additional 715 shares during the quarter. PFG Investments LLC’s holdings in Becton, Dickinson and Company were worth $612,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. WR Wealth Planners LLC raised its position in shares of Becton, Dickinson and Company by 1.4% in the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares in the last quarter. Clear Creek Financial Management LLC increased its holdings in Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Central Pacific Bank Trust Division grew its position in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC lifted its position in shares of Becton, Dickinson and Company by 3.6% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after acquiring an additional 48 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $238.99 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company has a fifty day moving average price of $237.52 and a 200-day moving average price of $235.03. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $259.92. The firm has a market cap of $69.07 billion, a price-to-earnings ratio of 52.64, a PEG ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same quarter last year, the business posted $2.96 EPS. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, equities research analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on BDX. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James decreased their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus lifted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.